TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04909489

Intervention type: OTHER
Intervention: cross-sectional study without intervention
Description: cross-sectional study without intervention

Intervention type: OTHER
Intervention: cross-sectional study without intervention
Description: cross-sectional study without intervention

Intervention type: OTHER
Intervention: cross-sectional study without intervention
Description: cross-sectional study without intervention
Study: NCT05720845

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VESPA
Description: Using Ventilatory strategy of prevent atelectasis for General Anesthesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional mechanical ventilation
Description: Conventional mechanical ventilation for General Anesthesia.
Study: NCT05979350

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Metagenomic next-generation sequencing
Description: Metagenomic NGS testing for pathogen identification will be done for airway and blood specimens using APGseq ® (Asia Pathogenomics, New Taipei City, Taiwan). The sample preparation for mNGS testing was as follows: 5-10 mL of whole blood were centrifuged at 1,600g for 10 min at 4°C to separate the plasma. Plasma samples were transferred to 2 mL sterile tubes for the following DNA or RNA extraction. In general, 300ul of plasma sample was used for DNA extraction. Total genomic DNA from samples were extracted using the column-based method (e.g. QIAamp DNA Microbiome Kit, Qiagen for DNA extraction; or QIAamp Viral RNA Mini Kit, Qiagen for RNA extraction, respectively), following the manufacturer's operational manual. The RNA was reverse transcribed and synthesized to double-stranded complementary DNA (ds cDNA) with SuperScript II Reverse Transcription Kit (Invitrogen).

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard work-up for pneumonia
Description: Endotracheal aspirates, blood samples, urine samples, and nasopharyngeal swabs were obtained from the patients as soon as possible after ICU admission. Bacterial culture was performed, with the use of standard techniques, on blood samples and endotracheal aspirates. Urine antigen detection was performed for detection of L. pneumophila and S. pneumoniae. A PCR assay was performed on nasopharyngeal swabs for the detection of influenza A and B viruses and SARS-CoV-2 viruses. Fungal or mycobacterial detections, and whether to use multiplex PCR for pathogen detection, such as the FilmArray system, were determined at the discretion of the physicians.
Study: NCT05055505

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Take home saliva kits
Description: Saliva kits will be made available at schools for pick up to support symptomatic testing using PCR for students, staff and family members.
Study: NCT06392724

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GEN6050X intravenous injection
Description: GEN6050X is an intravenously administered human DMD exon 50 skipping base editing drug.
Study: NCT06061939

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction training with Oclussion Cuff.
Description: A strength training program with blood flow restriction will be performed for 12 weeks, with 30-45 minute sessions on Mondays, Wednesdays and Fridays. Each session includes a warm-up, the main part with specific exercises and a cool-down with stretching.
Study: NCT05313035

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 protein subunit recombinant vaccine
Description: candidate vaccine manufactured by PT. Bio Farma

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 protein subunit recombinant vaccine
Description: candidate vaccine manufactured by PT. Bio Farma

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: the placebo is NaCl injection manufactured by PT. Bio Farma
Study: NCT06198205

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fundamental motor skills
Description: This will receive fundamental motor skills(FMS) program include 12 basic motor skills(running,hopping,galloping,leaping,jumping,sliding,strinking,dribbling,catching overhand throwing and underhand rolling)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular after school program
Description: This group will receive regular afterschool programs unstructured child's free play which include sliding, hide and seek, sea-saw, and running along with reading, drawing. Each intervention session lasted 60 minutes. The study will be conducted in the duration of 8 weeks with 3 sessions per week (total 24 sessions) will be given to the students.
Study: NCT05480930

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: paper-based clinical decision support (dCDS) tool
Description: The paper based clinical decision support tools currently employed at the TMDS that are used to triage, assess and generate treatment plans for pediatric patients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: digital clinical decision support (dCDS) tool
Description: The intervention is a digitized version of the paper based clinical decision support tools currently employed at the TMDS that are used to triage, assess and generate treatment plans for pediatric patients.
Study: NCT06272552

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PROMs and PREMs
Description: Participants are administered PROMs and PREMs at a given timeline adequate to each participant conditions for a duration of 2 years. The administration of PROMs is done by email using the REDCap platform. The research team and health care professionals have access to their patient\&amp;amp;#39;s results to aid in the patients clinical care.~Participants are administered a PREM once a year for two years. Only health care administrators, department heads and researchers will have access to the PREMs data, and this data will always be aggregated data to avoid identification of the patients. The administration of the PREM is done by email using the REDCap platform.~At recruitment and once a year, participants answer an evaluation questionnaire to measure the impact of completing PROMs and PREMs. This questionnaire is completed during a clinic visit.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PREMs
Description: Participants are administered a PREM once a year for two years. Only health care administrators, department heads and researchers will have access to the PREMs data, and this data will always be aggregated data to avoid identification of the patients. The administration of the PREM is done by email using the REDCap platform.~At recruitment and once a year, participants answer an evaluation questionnaire to measure the impact of completing PROMs and PREMs. This questionnaire is completed during a clinic visit.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: At recruitment and once a year, participants answer an evaluation questionnaire to measure the impact of completing PROMs and PREMs. This questionnaire is completed during a clinic visit.

Intervention type: OTHER
Group type: OTHER
Intervention: Healthcare professionals
Description: Healthcare professionals participating in the study answer an evaluation questionnaire before the implementation starts at their service and two years later to measure their perceptions about the implementation.
Study: NCT06251297

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot reflexology
Description: 30 minutes reflexology session
Study: NCT05079451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3BNC117-LS
Description: 3BNC117-LS will be administered by intravenous infusion (directly into the participants vein) over a period of 30 to 60 minutes. The total time needed to administer the study drug may be longer, based on factors such as participant tolerance. The participant's dose will be calculated using their most current weight on record.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10-1074-LS
Description: 10-1074-LS will be administered by intravenous infusion (directly into the participants vein) over a period of 30 to 60 minutes. The total time needed to administer the study drug may be longer, based on factors such as participant tolerance. The participant's dose will be calculated using their most current weight on record.
Study: NCT02055196

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: carboxylesterase-expressing allogeneic neural stem cells
Description: Given via intracerebral catheter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT06408480

Intervention type: DIAGNOSTIC_TEST
Intervention: Neonatologist-performed lung ultrasound
Description: lung ultrasound conducted in min 5, 15, 30, 60 min after birth in late preterm and term infants

Intervention type: DIAGNOSTIC_TEST
Intervention: Neonatologist-performed lung ultrasound
Description: lung ultrasound conducted in min 5, 15, 30, 60 min after birth in late preterm and term infants
Study: NCT05641181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRB4101
Description: After the participants who signed the informed consent have been screened by the inclusion criteria, those who meet the inclusion criteria and those who do not meet the exclusion criteria will receive the following 6 dose groups in order from low to high:~100mg, 200 mg, 400 mg, 800 mg, 1200 mg, 1600 mg In each dose group, 8 participants will be enrolled to receive the drug, including 6 receiving CRB4101 tablets and 2 receiving placebo.
Study: NCT04822870

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quadratus lumborum block
Description: Quadratus lumborum block is an effective nerve block method in post-cesarean section analgesia. It is a relatively new technique that may provide analgesic effect in somatic pain and visceral pain, but has not been verified yet.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: iliohypogastric/ilioinguinal nerve block
Description: Iliohypogastric/ilioinguinal nerve block is a widely used nerve block technique. It can provide somatic analgesia effect in post-cesarean section.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: epidural analgesia
Description: Epidural analgesia is a traditional analgesia method. Epidural morphine can provide effective analgesia but may cause plenty adverse effect.
Study: NCT05641181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRB4101
Description: After the participants who signed the informed consent have been screened by the inclusion criteria, those who meet the inclusion criteria and those who do not meet the exclusion criteria will receive the following 6 dose groups in order from low to high:~100mg, 200 mg, 400 mg, 800 mg, 1200 mg, 1600 mg In each dose group, 8 participants will be enrolled to receive the drug, including 6 receiving CRB4101 tablets and 2 receiving placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRB4101
Description: After the participants who signed the informed consent have been screened by the inclusion criteria, those who meet the inclusion criteria and those who do not meet the exclusion criteria will receive the following 6 dose groups in order from low to high:~100mg, 200 mg, 400 mg, 800 mg, 1200 mg, 1600 mg In each dose group, 8 participants will be enrolled to receive the drug, including 6 receiving CRB4101 tablets and 2 receiving placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRB4101
Description: After the participants who signed the informed consent have been screened by the inclusion criteria, those who meet the inclusion criteria and those who do not meet the exclusion criteria will receive the following 6 dose groups in order from low to high:~100mg, 200 mg, 400 mg, 800 mg, 1200 mg, 1600 mg In each dose group, 8 participants will be enrolled to receive the drug, including 6 receiving CRB4101 tablets and 2 receiving placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRB4101
Description: After the participants who signed the informed consent have been screened by the inclusion criteria, those who meet the inclusion criteria and those who do not meet the exclusion criteria will receive the following 6 dose groups in order from low to high:~100mg, 200 mg, 400 mg, 800 mg, 1200 mg, 1600 mg In each dose group, 8 participants will be enrolled to receive the drug, including 6 receiving CRB4101 tablets and 2 receiving placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRB4101
Description: After the participants who signed the informed consent have been screened by the inclusion criteria, those who meet the inclusion criteria and those who do not meet the exclusion criteria will receive the following 6 dose groups in order from low to high:~100mg, 200 mg, 400 mg, 800 mg, 1200 mg, 1600 mg In each dose group, 8 participants will be enrolled to receive the drug, including 6 receiving CRB4101 tablets and 2 receiving placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After the participants who signed the informed consent have been screened by the inclusion criteria, those who meet the inclusion criteria and those who do not meet the exclusion criteria will receive the following 6 dose groups in order from low to high:~100mg, 200 mg, 400 mg, 800 mg, 1200 mg, 1600 mg In each dose group, 8 participants will be enrolled to receive the drug, including 6 receiving CRB4101 tablets and 2 receiving placebo.
Study: NCT05612152

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Referral to Quitline
Description: An electronic referral to the state quitline is placed. This prompts the quitline to proactively call the patient to enroll in counseling services.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Choose2Quit
Description: An electronic referral to the Choose2quit tobacco cessation navigator is placed. This prompts the navigator to call the patient to review options for tobacco cessation counseling, tobacco cessation medications and other supports.
Study: NCT04838951

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ENDO-AID CADe
Description: ENDO-AID CADe will be used during the withdrawal process of the colonoscopy.
Study: NCT04898439

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: greening of the school environment
Description: The school will be greened and biodiversity will be increased. This will be done on the playground and area around the school. Special needs corners for playing, relaxing or gardening will be installed.
Study: NCT05331677

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: correction of deformities around the knee with external fixator
Description: minimally invasive surgery
Study: NCT06401239

Intervention type: OTHER
Intervention: Dyadic expectations about the ARF survivor's perceived health 6 months after hospital discharge
Description: Dyad members' expectations will be collected at baseline and at 3- month follow-up assessments using a visual analogue scale (VAS) ranging from 0 - 100, similar to the EQ-5D-VAS.

Intervention type: OTHER
Intervention: Self-efficacy
Description: Self-efficacy in both dyad members will be assessed at 3- and 6-month follow-up assessments using the Generalized Self-Efficacy Scale (GSE). The GSE has 10 items scored on a 4-point scale. U.S. adult population norms are available.

Intervention type: OTHER
Intervention: Concordant expectations/shared appraisal of ARF survivor's health 6 months after hospital discharge
Description: Dyad members' expectations will be collected at baseline and at 3- month follow-up assessments using a visual analogue scale (VAS) ranging from 0 - 100, similar to the EQ-5D-VAS.
Study: NCT06237959

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Keranat™
Description: 300 mg/capsule(proso millet and wheat extract 600 mg/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 300 mg/capsule(600 mg/day as placebo)
Study: NCT04955717

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chlamydia trachomatis and Neisseria gonorrhoeae screening using the GeneXpert
Description: Chlamydia trachomatis and Neisseria gonorrhoeae testing using the GeneXpert
Study: NCT05449184

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balloon Eustachian Tuboplasty with Tympanostomy Tube Insertion
Description: Under local or general anesthesia, insert a balloon into one Eaustachian tube and inflate it for up to two minutes. The balloon is then removed. Subsequently, pierce the tympanic membrane in the front and lower quadrants, suck the tympanic effusion, and then insert a tympanic ventilation tube. The tube will be removed 6 months later.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Tympanostomy Tube Insertion
Description: Under local or general anesthesia, pierce the tympanic membrane in the front and lower quadrants, suck the tympanic effusion, and then insert a tympanic ventilation tube. The tube will be removed 6 months later.
Study: NCT05204446

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GROW Project
Description: (GROW Group): Live interactive telehealth-based group meetings will be held for 60 minutes per week over six weeks using Zoom for Telehealth, a HIPAA-compliant platform provided by the PI's institution. A teen group (n=8 per cohort) and a parent group (n=8 per cohort) will be run concurrently but separately, with coordinating topics. Each group meeting will introduce and facilitate discussion of information and CBT-oriented topics for coping and management of CD. Participants will be encouraged to use their audio and video to engage with the interventionist and each other. Between sessions, resources sent through text-based SMS messages using Twilio HIPAA-compliant software 3x/week as reminders of skills and goals for the week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GROW+ Project
Description: (GROW+ Group): Will include the GROW Project with enhanced behavioral strategies and materials identified from phase 2 data (e.g., group discussion about GIP testing, text-based check-ins, etc.) In addition, teens in GROW+ will be encouraged to complete a minimum of 2 GlutenDetect tests per week (12 total) and report results in REDCap (Research Electronic Data Capture, a secure, web-based survey application) throughout the intervention.
Study: NCT05563610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin 500mg
Description: Patients screened to be low risk of penicillin allergy will be randomized to receive amoxicillin dose or not
Study: NCT04675333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: evorpacept
Description: IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: IV Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pembrolizumab
Description: IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin/Carboplatin; 5FU
Description: IV Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin/Carboplatin; 5FU
Description: IV Q3W
Study: NCT05640440

Intervention type: DIAGNOSTIC_TEST
Intervention: Executive function testing
Description: Assessment of executive function subdivision

Intervention type: DIAGNOSTIC_TEST
Intervention: Executive function testing
Description: Assessment of executive function subdivision
Study: NCT04945083

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Nutritional Pudding
Description: High Calorie, High Protein pudding
Study: NCT05564780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RASI and/or a single pill combination based RASI
Description: The participants in the Treatment group will begin with a single category antihypertensive drug to control their blood pressure, for example, perindopril. If the blood pressure cannot be controlled under 130/80 mmHg, another type of antihypertensive drug will be added.
Study: NCT05900700

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eYST website
Description: The website is a psychoeducational, social support program for adolescents at risk for suicide
Study: NCT06206538

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block
Description: Based on the invention above, the patients in the observation group were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation therapy
Description: he study lasted 20d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Particularly, due to dysphagia, the patients enrolled might face difficulty in eating. For patients who were able to finish intake via mouth by compensatory means, the consistency, type, and size of food bolus was arranged. For those who cannot acquire sufficient nutrition through oral intake, the nasogastric tube feeding (NGT) was provided.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation therapy
Description: he study lasted 20d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Particularly, due to dysphagia, the patients enrolled might face difficulty in eating. For patients who were able to finish intake via mouth by compensatory means, the consistency, type, and size of food bolus was arranged. For those who cannot acquire sufficient nutrition through oral intake, the nasogastric tube feeding (NGT) was provided.
Study: NCT04718623

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative determination of serum Presepsin (sCD-14), and Syndecan-1 concentrations
Description: Quantitative determination of serum Presepsin (sCD-14), and Syndecan-1 concentrations by ELISA technique

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative determination of serum Presepsin (sCD-14), and Syndecan-1 concentrations
Description: Quantitative determination of serum Presepsin (sCD-14), and Syndecan-1 concentrations by ELISA technique